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Background : Mucin producing cystic neoplasms, such as mucinous cystic tumor (MCT) and
intraductal papillary mucinous tumor (IPMT) of the pancreas, are uncommon but become increas-
ing in their incidences. The pathologic classification and biologic potential of these neoplasms
remain the subject of controversy. Methods : The Gastrointestinal Pathology Study Group of
the Korean Society of Pathologists analyzed the clinicopathologic characteristics of 85 cases
of MCT and 72 cases of IPMT and examined the expression patterns of p53, CEA and MUC1.
Results : IPMT was located largely in the head, and showed connection with the main pan-
creatic duct (MPD, 68.1%), no ovarian-like stroma (0/72), and presence of intervening intra-
tumoral normal or atrophic parenchyma. On the other hand, MCT was located largely in the
tail (73%), and showed common ovarian-like stroma (66/80), rare connection with the MPD
(7/85) and no intervening pancreatic parenchyma. CEA and p53 immunoexpressions were
significantly increased from adenoma through borderline to carcinoma, but MUC 1 was expressed
only in the invasive carcinoma among cases of MCT and IPMT. Conclusions : The tumor
location, ovarian-like stroma, connection with the MPD and intratumoral intervening nonneo-
plastic tissue were helpful in the differential diagnosis between IPMT and MCT. CEA and p53
expressions can be indicators of malignancy, while MUC 1 expression can indicate invasion.
Key Words : Mucinous Cystic Tumor-Intraductal Papillary Mucinous Tumor-Pancreas
Jin Hee Sohn∙Kyung Me Kim
Seoung Wan Chae∙Woo Ho Kim
Woo Sung Moon∙Young Nyun Park
Chul Gun Park∙Eunsil Yu
Hee Kyung Jang∙Hee Jin Jang
Jong Jae Jung∙Jin Sook Jung
So Young Jin∙Jong Sang Choi
Dae Young Kang
Prevalence and Clinicopathologic Features of Mucinous Cystic Tumor
and Intraductal Papillary Mucinous Tumor of Pancreas in Korea
Corresponding Author
Dae Young Kang, M.D.
Department of Pathology, College of Medicine,
Chungnam National University, 6 MunHwa-1-dong,




This study was supported by a 2001-Grant from the
Korean Academy of Medical Sciences, KMA.
The Gastrointestinal Pathology Study
Group of the Korean Society of 
Pathologists
Received : April 24, 2003
Accepted : August 9, 2003
INTRODUCTION
Cystic neoplasms of the pancreas are rare and have relatively
similar characteristics on modern imaging modalities.1,2 But the
incidences of these cystic neoplasms have been increasing, and
the origin of the neoplastic cells and their biologic aggressiveness
are still controversial.1,3-17 The spectrum of cystic neoplasms en-
compasses biologically diverse diseases and can be categorized
into serous tumor, mucinous cystic tumor (MCT) and intraduc-
tal papillary mucinous tumor (IPMT).1,18 IPMT and MCT are
classified as separate categories of pancreatic exocrine tumor.3,19
It has been known that these tumors are potentially malignant,
but have good prognosis.3,18,20,21 The recognition and differenti-
ation of MCT and IPMT from other cystic disorders of the pan-
creas are crucial because of their malignant potential.1 Howev-
er, differential diagnosis between IPMT from MCT remains a
challenge because clear criteria for differentiation have not been
established yet, and clinical manifestations are variable and not
correlated with the pathologic features. In MCT and IPMT, there
are both adenoma and carcinoma lesions, but it is not always pos-
sible to differentiate the two lesions, especially before surgical
resection. Thus, some authors have suggested that the patholog-
ic features such as degree of cellular atypism and stromal invasive-
ness should be used as prognostic factors.21-23 Several previous
reports suggested the presence of adenoma-carcinoma sequences
in these neoplasms.21,24-27
In Korea, the incidence of mucin-producing cystic neoplasms
of the pancreas is very low.28 Morever, the clinical characteristics,
prevalent sites, macroscopic and microscopic findings and prog-
nostic factors have yet to be clarified. Therefore, the Gastrointesti-
nal Pathology Study Group of the Korean Society of Pathologists
collected cases of MCT and IPMT from hospitals throughout the
Prevalence and Pathologic Findings of Pancreatic MCT and IPMT  271
country. We then examined clinicopathologic features, including
degree of histopathologic abnormalities and prognosis, and immu-




This study included surgically resected 157 cases of pancreatic
mucin producing cystic neoplasms from January 1990 to June
2000 that were retrieved from the files of the department of
pathology of 21 hospitals located in different parts of Korea.
They were composed of 85 cases of MCT and 72 cases of IPMT.
Cases lost during follow-up, cases without exact clinicopatho-
logic data, cases with indefinite data, recent cases, and cases of
ductal carcinoma showing cystic change were discarded.
Methods
Evaluation of clinicopathologic findings 
A committee reviewed the slides and collected representative
slides having the highest degree of dysplasia, well preserved blocks
and clinicopathologic data as well as radiological findings from
the hospital records and from pathologic reports. Subsequently,
committee members reviewed the slides all together several times
with 10 head microscopes. Each case was then divided into MCT
and IPMT, and classified into adenoma, borderline, non-invasive
carcinoma or invasive carcinoma. We correlated these data with
the other clinicopathologic parameters and follow-up data. For
standardizing the clinicopathologic features, we made a com-
mon data sheet containing age, sex, symptoms and signs, radio-
logic and pathologic features. Pathologic diagnosis and classifi-
cation were done according to WHO classification.14
Immunohistochemical staining
Immunohistochemical staining was performed in 101 cases
following the standard avidin-biotin peroxidase conjugate method.
At first, several 4 m-thick sections were obtained from the paraf-
fin-embedded tissue blocks. They were deparaffinized in xylene
and rehydrated in graded concentrations of alcohol. Endogenous
peroxidase activity was blocked by treating the sections with 0.3
% hydrogen peroxide for 5 minutes. In cases of p53 and MUC1,
sections were treated in a microwave oven for 10 minutes for anti-
gen retrieval. For CEA the pretreatment was not done. They were
treated with different primary antibodies for 40 minutes (Table
1). A Chem MateTM EnvisionTM detection kit (DAKO Corpora-
tion, CA, USA) was used for secondary antibody at room temper-
ature for 30 minutes. We used 3,3-diaminobenzidine for visual-
izing the immunoreaction, and Mayer’s hematoxyline for coun-
terstaining. Colonic adenocarcinoma was used as a positive con-
trol for CEA, and mammary carcinoma was for p53 and MUC1.
Normal serum was used instead of primary antibodies for nega-
tive controls.
Interpretation of immunohistochemical staining
When a definite brown nuclear staining was present for p53,
regardless of the staining intensity, it was considered positive, but
cells with very weak equivocal staining were considered negative.
Staining patterns of the diffuse type (positive staining in most
areas) or nested type (positive staining in cell nests composed of
more than 20 cells) were regarded as having p53 overexpression.
Cases showing positive reactions in less than 10% of the cells were
considered as negative. Diffuse cytoplasmic stainings for MUC1
and CEA were considered as positive. Cases showing only lumi-
nal positivity and positive reaction in less than 10% of cells were
considered as negative. Quantitative grading was not done.
Statistical analysis
Statistical analysis was performed using the SAS procedures for
means, t-test and univariate analysis (SAS institute, Carry, NC,
U.S.A.). We computed the mean, standard deviation and correla-
tion coefficient of each feature using Spearman’s nonparametric
correlation test. The student’s t-test was used to determine the




Patients included 50 men and 107 women (M:F=1:2.1) with
a mean age of 53.02 (range 5-92) years (Table 2). According to
′
*IP: incubation period.
Antibody Source Dilution IP*
CEA DAKO monoclonal, CA, U.S.A. prediluted form 40 min.
p53 DAKO monoclonal DO-7, CA, U.S.A. prediluted form 40 min.
MUCI Novocastra Laboratory Ltd, UK ×200 40 min.
Table 1. Antibodies used for immunohistochemical stain
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the tumor type, MCT was more common in women (p<0.0001)
and IPMT was slightly more common in men. Clinical symptoms
varied with abdominal pain being the most common symptom
(41 cases). The other symptoms were anorexia (30 cases), abdom-
inal discomfort (20 cases), and a palpable mass (16 cases). Twen-
ty-one cases were incidentally detected. Pancreatitis was associ-
ated only in 39 cases of IPMT out of 91 cases with abdominal
symptoms.
Macroscopically, MCTs were unilocular or multilocular cystic
tumors containing abundant mucinous material. Adenoma cases
were largely unilocular, and became multilocular more frequent-
ly in malignant cases. Connection with the main pancreatic duct
(MPD) was noted in 7 cases (8.2%), was absent 64 cases (75.3%)
and was not described in 14 cases. The tumor size was variable,
ranging from 1 cm to 31 cm (mean: 6.88 cm); the mean sizes of
adenoma (5.96 cm), borderline (6.68 cm), non-invasive carcino-
ma (4.23 cm) and invasive carcinoma (10.62 cm) suggested an
increasing tendency of the tumor according to the malignant
potential. The tumor size was not described in 16 cases (Table 2).
The tail was the commonest site in MCT (62 cease), especially
in adenoma cases, while carcinoma cases had a tendency to involve
the whole pancreas (Table 3). 
IPMTs showed diffuse or segmental dilatation of the MPD with
abundant mucin secretion. Connection with the MPD was noted
in 49 cases (68.1%) and uncertain in 23 cases. The tumor size of
IPMTs ranged from 0.7 cm to 23 cm (mean: 5.76 cm); the mean
sizes of adenoma, borderline, non-invasive carcinoma and inva-
sive carcinoma were 4.73 cm, 6.36 cm, 5.43 cm and 8.75 cm,
respectively, which exhibited no difference according to the malig-
nant potential. The tumor size was not described in 10 cases.
IPMT mainly involved the head and the tail (Table 3).
Microscopically, the cyst wall of MCTs consisted of thick fibrous
MCT, mucinous cystic tumor; IPMT, intraductal papillary mucinous
tumor; MPD, main pancreatic duct; NLP, normal pancreatic tissue.
MCT IPMT
Age 5-92 (mean 46.47) 32-77 (mean 60.87)
Sex (M:F) 9:76 41:31
Size 1-31 cm (6.88 cm) 0.7-23 cm (5.76 cm)
Pancreatitis 0/28 39/63
Gross Uni or multilocular cyst multiple cyst
Connection with MPD 7/85 49/72
Lining cell mucus containing mucus containing
cuboidal/columnar cuboidal/columnar
Ovarian type stroma 66/80 0/72
NLP between cyst 1/85 72/72
Table 2. Clinicopathologic characteristics of intraductal papil-
lary mucinous tumor and mucinous cystic tumor
*: Cases arising in body-tail or tail of the pancreas. MCT, mucinous
cystic tumor; IPMT, intraductal papillary mucinous tumor; Non-inv, non
invasive; Inv, invasive; NS, not sperified.
Pathologic diagnosis Head Body Tail* Whole NS Total
MCT 9 5 62 2 7 85
Adenoma 8 2 33 0 5 48
Borderline 1 1 15 1 0 18
Non-inv Carcinoma 0 1 4 0 0 5
Inv Carcinoma 0 1 10 1 2 14
IPMT 29 8 23 9 3 72
Adenoma 3 4 1 0 0 8
Borderline 19 3 9 1 2 34
Non-inv Carcinoma 7 1 10 7 0 25
Inv Carcinoma 0 0 3 1 1 5
Table 3. Distribution of mucinous cystic neoplasm of pancreas
according to the site
Fig. 1. Adenoma of mucinous cystic tumor. Mucin containing tall
columnar lining epithelial cells with basally located nuclei are
noted. Subepithelial layer exhibits ovarian-like stroma.
Fig. 2. Borderline mucinous cystic tumor. Papillary epithelial cells
showing low or moderate cellular atypia are present.
tissue, which was partly hyalinized and partly composed of cel-
lular stroma with spindle cells resembling ovarian stroma. All of
the MCTs had cuboidal or columnar lining epithelial cells with
areas of papillary projections. The amount of mucin, degree of
proliferation and atypia of the neoplastic cells were various from
case to case and from area to area within the tumor (37/85 cases).
In adenomas, cuboidal cells without cellular atypia lined the cyst
walls. Most of the cases did not have papillary structures with
fibrovascular cores. Nuclei were located mainly in the basal por-
tion, and pseudostratification was not noted (Fig. 1). Ovarian-
type stroma was noted in 34 cases (79%) out of 43 cases. Normal
or atrophic pancreatic tissue within the tumor was noted in only
one case. In 18 cases of borderline MCTs, most cases exhibited
papillary structures lined by columnar epithelia with low or mod-
erate degree of cellular atypism (Fig. 2). Ovarian-type stroma was
noted in 13 cases (72%) out of 18 cases. Five cases were non-inva-
sive carcinomas of MCT, which exhibited a definite malignant
change of epithelial cells with cellular proliferation, hyperchro-
masia, decreased mucin, frequent mitosis and nucleoli without
evidence of invasion (Fig. 3). Ovarian-like stroma was noted in
all cases. Fourteen cases were invasive carcinomas showing ovar-
ian-type stroma with severe cellular atypia and diffuse invasion
(Fig. 4). Four men and ten women did not have ovarian-type
stroma, which suggested that ovarian-type stroma was not con-
comitant in all MCTs, even in female patients. 
IPMT exhibited no ovarian-type stroma in all cases. IPMTs
consisted of papillary proliferation of cuboidal or columnar epithe-
lial cells with small fibrovascular stalks. The cytoplasmic features
and grades of cellular atypia of these neoplastic cells varied from
case to case and from area to area within the tumor (62/72 cases).
Adenoma cases of IPMT showed dilated ducts having papillary
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Fig. 3. Non-invasive malignant mucinous cystic tumor. Severe
cellular atypia with hyperchromatic nuclei and frequent mitosis
are noted.
Fig. 5. Adenoma of Benign intraductal papillary mucinous tumor.
Dilated duct containing papillary structure is noted. Papillae are
lined by mucin containing tall columnar cells without cellular atyp-
ia. Ovarian-type stroma is not present.
Fig. 6. Borderline intraductal papillary mucinous tumor. More com-
plex papillae with stratified columnar cells are noted.
Fig. 4. Invasive malignant mucinous cystic tumor. Stromal inva-
sion by the atypical cells and glands is noted.
proliferation of cuboidal mucin-profucing cells (Fig. 5). Between
these dilated ducts, there was normal or inflamed atrophic pan-
creatic tissue. Cellular atypism or cellular crowding was not iden-
tified. Borderline IPMT showed stratified cuboidal epithelial cells
having moderate atypism in all 34 cases (Fig. 6). Nucleoli were
enlarged and stratified and moved upward from basal locations
(Fig. 7). Adenoma area was accompanied in many cases. One case
exhibited diffuse borderline IPMT features in the liver, even th-
ough borderline lesions were focally noted in the pancreas with
the background of adenoma. Carcinoma cases of IPMT exhibit-
ed severe nuclear atypism, irregular nuclear arrangement, promi-
nent nucleoli, hyperchromasia and frequent mitosis (Fig. 8, 9).
Invasion was noted in 5 cases. In those cases, stromal fibrosis,
edema and inflammatory cell infiltration were noted as reactions
to invasion (Fig. 10). One invasive carcinoma case showed squa-
mous metaplasia. The amount of mucin in the cytoplasm was
inversely correlated with the increase of malignancy. 
We followed-up 122 cases for 1 to 126 months. Among them,
104 subjects were alive and 18 subjects were dead. The latter
group consisted of 4 adenomas of MCT, 3 borderline MCTs, 2
invasive carcinomas of MCT, 3 adenomas of IPMT, 3 borderline
IPMTs, and 3 non-invasive carcinomas of IPMT, which showed
no statistically significant correlation between types of tumor and
survival. The causes of death in the adenoma patients with MCT
and IPMT were not directly related to the tumor: Four patients
died within 3 months after operation due to postoperative com-
plications. One patient with adenoma (1.3 cm) of IPMT died 15
months after operation with an unrelated cause; one patient with
a 9.5 cm-sized adenoma of MCT, had died 2 years after operation.
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Fig. 7. Borderline intraductal papillary mucinous tumor. Lining
cells show enlarged and stratified nuclei with moderate cellular
atypia and upward location.
Fig. 9. Non-invasive malignant intraductal papillary mucinous
tumor. Tumor cells show severe nuclear atypia, prominent nucle-
oli and hyperchromasia with many mitosis. Ovarian-type stroma
is not present.
Fig. 10. Invasive malignant intraductal papillary mucinous tumor.
Stromal invasion by the malignant cells is present.
Fig. 8. Non-invasive malignant intraductal papillary mucinous
tumor. More complex and proliferative papillae are present in the
dilated ducts. Atrophic pancreatic tissue is noted within the neo-
plasm.
We could not obtain the information pertaining to the remain-
ing 1 case. Borderline and carcinoma cases revealed tumor-relat-
ed deaths.
Immunohistochemical findings
Immunohistochemical stainings for p53, CEA and MUC1
were done in 55 cases of MCT and 46 cases of IPMT (Table 4).
In cases of MCT, CEA was positive in 11 cases (20.0%), p53
in 9 cases (16.4%) and MUC1 in 10 cases (18.2%). A gradual
stepwise increase in the frequency of overall expression of CEA
and p53 was observed with the increase of cellular atypia from
adenoma to carcinoma (p<0.05) (Fig. 11-13). In cases of invasive
carcinoma, both invasive and non-invasive areas showed positive
reactions to CEA. But one case exhibited positive immunoexpres-
sion only in non-invasive area. On the other hand, MUC1 was
expressed only in the invasive carcinoma cases (p<0.05) (Fig. 14).
Correlations of the immunoexpression showed statistical signif-
icance between p53 and MUC1 (p<0.05), between CEA and
MUC1 (p<0.05), and between CEA and p53 (p=0.001).
In cases of IPMT, CEA immunoexpression also increased from
adenoma through borderline to carcinoma, which was statisti-
cally insignificant (p=0.056) (Fig. 15). We were unable to eval-
uate p53 immunoexpression, because there were no positive cases.
MUC1 immunoreactivity was positive only in invasive carcino-
ma cases, which was statistically significant (p<0.05) (Fig. 16).
MUC1 immunoexpression also correlated significantly with that
of CEA (p=0.022). Therefore, CEA and p53 immunoreactivities
were helpful in identifying the degree of malignancy in MCT,
and MUC1 immunopositivity was an useful marker for invasion
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Fig. 11. Intracytoplasmic expression for CEA is noted in the papil-
lary epithelial neoplastic cells of borderline mucinous cystic tumor.
Fig. 13. Invasive malignant mucinous cystic tumor. Immunohisto-
chemical stain for p53 shows positive nuclear stain both in the
invasive portion and lining malignant cells. 
Fig. 12. Invasive malignant mucinous cystic tumor. Immunoex-
pression for CEA is noted in the malignant epithelial cells. But inva-
sive portion does not show positive reaction.
MCT, mucinous cystic tumor; IPMT, intraductal papillary mucinous
tumor; Non-inv, nov invasive; Inv, invasive; *: p<0.05 at the Chi-Square
test (Likelihood Ratio) between adenoma, borderline, non-invasive car-
cinoma and invasive carcinoma, **: p<0.05 at the Chi-Square test
(Likelihood Ratio) between invasive carcinoma and other categories.
Type No. CEA No. (%) p53 No. (%) MUCI No. (%)
MCT 55 11 (20.0)* 9 (16.4)* 10 (18.2)**
Benign 24 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 14 3 (21.4) 1 (7.1) 0 (0.0)
Non-inv Carcinoma 3 0 (0.0) 0 (0.0) 0 (0.0)
Inv Carcinoma 14 8 (57.1) 8 (57.1) 10 (71.4)
IPMT 46 11 (23.9) 0 (0.0) 4 (8.7)**
Benign 5 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 20 4 (20.0) 0 (0.0) 0 (0.0)
Non-inv Carcinoma 17 4 (23.5) 0 (0.0) 0 (0.0)
Inv Carcinoma 4 3 (75.0) 0 (0.0) 4 (100)
Table 4. Immunoexpression of the mucinous cystic tumors and
intraductal papillary mucinous tumors
in both MCT and IPMT.
DISCUSSION
Our study showed that IPMT developed largely in the head
and the tail of the pancreas of older men and MCT developed in
the tail of middle-aged women. This result was identical to other
reports.20,21,24,26 Ovarian-type stroma was present in 66 cases (82.5
%) out of 80 cases of MCT, but none of the 72 cases of IPMT
showed ovarian-type stroma. These results were also in line with
other reports3,20 and the ovarian-type stroma is one of the histo-
logical differential points between IPMT and MCT. Moreover,
there was intervening atrophic or normal-appearing pancreatic
tissue between cystic neoplastic lesions in all cases of IPMT, while
only in one case of MCT. Therefore, this feature is one of the his-
tological points for differential diagnosis between the two. How-
ever, there is no identifiable report that definitively describes this
feature as a differential point. Many cases of both MCT and IPMT
showed variable grades of atypism from borderline to invasive
carcinoma in the tumor according to the site. This result agrees
with other reports.1,4,12,20,21 Thus, it suggested that a careful and
thorough examination of sections should be mandatory for accu-
rate diagnosis. Although there are some difficulties in differen-
tiating branch-type IPMT from MCT macroscopically and micro-
scopically,21,27 clinicopathologic features such as location, presence
of ovarian-type stroma and intercystic pancreatic tissue, connec-
tion with the MPD are very helpful features for differential diag-
nosis. Therefore, a definite diagnosis requires the careful explo-
ration of clinical findings and macroscopic and microscopic fea-
tures.
The difference of the prognoses between patients with IPMT
and MCT was not statistically significant. Overall prognosis was
good with only 18 deaths out of 122 cases. Among the deaths,
tumor grade and type were similar, and causes of death were not
related with the tumors in some cases. These results were similar
those of other reports.20,21,23,27
The immunohistochemical examination showed very meaning-
ful results. In MCT, CEA and p53 immunoexpressions increased
from adenoma through borderline to carcinoma, which was sta-
tistically significant. Benign and normal ductal epithelial cells
showed only weak positive reactions for CEA, along the luminal
border but the transition to diffuse cytoplasmic expression was
noted in the site of the malignant transformation. These results
are in line with previous reports.5,6,11,12 In one case of invasive car-
cinoma, a positive reaction was noted only in the non-invasive
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Fig. 14. Invasive malignant mucinous cystic tumor. Immunoex-
pression for MUC1 is noted only in the invasive neoplastic cells.
Fig. 16. Invasive malignant intraductal papillary mucinous tumor.
Strong cytoplasmic immunoexpression for MUC1 is noted only in
the invasive neoplastic cells.
Fig. 15. Non-invasive malignant intraductal papillary mucinous
tumor. Strong cytoplasmic immunoexpression for CEA is present.
area. But other cases showed positive reactions in both invasive
and non-invasive areas. This pattern was not described in other
reports, suggesting the need for further study. In IPMT, CEA
immunoexpression increased from adenoma through borderline
to carcinoma, which was not statistically significant. This result
is in accord with that of the previous study.11 As with MCT, MUC1
was expressed only in cases of invasive carcinoma, which corre-
sponds with those of the previous reports,8,9,16 and suggests that
MUC1 is a good marker for the evaluation of invasion. Therefore,
CEA and p53 expressions are helpful for grading these neoplasms
because their immunoexpressions increase with the increase of
atypism. On the other hand, MUC1 is helpful for the evaluation
of invasion. 
In conclusion, MCT and IPMT showed varied degrees of atyp-
ism and proliferation in and between tumors, suggesting the need
for the thorough and careful examination of sections. We also
found that several features such as presence of nonneoplastic
parenchyma between dilated ducts, tumor location, connection
with the MPD and presence of ovarian-type stroma were very
useful for the differentiation between MCT and IPMT. Moreover,
CEA, p53 and MUC1 appeared to be good markers for evalu-
ating atypism and prognosis.
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